Pharmacokinetics Flashcards
What is dosing schedule for carbimazole
OD (half life: 6 hours)
PK of Levothyroxine
Route
Bioavailablity
Oral and empty stomach
Bioavailiblity: 80%
PK of T3/Leothyronine
Route:
Bioavailablity:
Route:Oral/IV
Bioavailablity:100%
PK of Alpha glucosidase inhibitors
Route
Frequency
How to take
Metabolism
Absorption
Specific
Oral
TDS
First bite of meal
Adjuvant to diet
Metabolism
Acarbose: intestinal bacteria metabolism (colon)
Miglitol and Voglibose:
Both no metabolites
Absorption
Miglitol: Well-absorption
PK of GLP 1 analogues
Route
Specfic frequency
Route: S/C
Exenatide: BD
Lixisenatide: OD
PK of gliptins
Route
Elimination
M/I
Metabolism
D/I
Route: Oral
Elimination
Renal
Alo, Sita, Saxa
M/I dose adjusment in Renal dysfunction
Entero-Hepatic
Lina
Metabolism
CYP450 3A4
Inducers:Rifampicin
Inhibitors: Ketoconazole, Diltiazem
Pramlinitide
Route
Duration of Action
Syringe
Why?
Subcutaneous
2-3 hours
Different syringe than INSULIN
If same: reduce INSULIN by 50%
(Increased risk of hypoglycemia)
PK of Shortest and Fastest acting Insulin: Afrezza
Route:
Catridge:
When:
Inhalational
Colour coded
Blue: 4 units
Green: 8 units
Yellow: 12 units
Before meal
PK of short but fast acting Insulin:
Lispro
Glulisine
Aspart
Effect time:
When:
Route:
15 minute
15-20 minutes before or after a meal
IV
PK of Short but slow acting insulin: Regular insulin
Effect time:
Route:
When:
45 minutes to 1 hour
S/C
30 minutes to 1 hour before meal
PK of intermediate acting insulin: Neutral Protamine Hagedorn
Lente Insulin
Route:
S/C
PK of long acting Insulin:
Detemir
Glargine
Degludec
Why long-acting?
Route:
Which is longest acting?
Saturated fatty acid-> ^^ PPB
Acidic pH form crystals or precipitate which break downs slowly
Hexadecanoic acid which form hexamers with tissue and slowly release as monomers
S/C
Degludec
Which insulin the site of injection doesn’t affect absorption rate
Glargine
When to use this route of insulin adminstartion ?
(5) hospital settings
Subcutaneous: for ease and convinence for patients
Syringes pumps and pens
I/V: in hospital settings in emergency treatement requiring close monitoring of blood glucose levels such as in
Diabetic Ketoacidosis
Hyperosmolar hyperglycemic state
Severe hyperkalemia
Beta-blocker toxicity
Calcium-channel blocker toxicity
Site of insulin S/C to not be used jn abdomen
Peri umblical region